This trial is evaluating whether RP-6306 will improve 4 primary outcomes and 8 secondary outcomes in patients with Solid Tumors, Advanced Solid Tumors. Measurement will happen over the course of Up to 90 days after last administration of study intervention.
This trial requires 120 total participants across 2 different treatment groups
This trial involves 2 different treatments. RP-6306 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"It is not possible to cure cancer, and the question 'Can cancer be cured? can be answered in different ways, because cure is not a precise scientific term. The answer to 'can' is no. But how can we find the cure? This answer is, 'if I know exactly what we're looking for, we can then use the cure to target our search and find the cure: in other words, the disease is a target (the target of the cure) rather than the cure: a target that is located on-line to a cure, in the form of the cure itself, which exists in the world rather than on the mind of the patients." - Anonymous Online Contributor
"Symptoms of cancer can range from fatigue and loss of appetite, to persistent coughing, to shortness of breath, to vomiting, to unexplained weight loss, loss of appetite, fatigue and shortness of breath." - Anonymous Online Contributor
"The common treatments for cancer are surgery, chemo/radiotherapy and biologic therapies, while for some specific cancers there are therapies unique to those conditions - namely, palliative care for patients with advanced cancer, who often suffer from pain, and immunotherapy to enhance immune responses in patients with inoperable cancer. Finally, many patients are treated with a variety of complementary medicines to manage their cancer. Commonly used supplementary treatments include herbal medicine (including dietary supplements), acupuncture, massage, reflexology, nutrition, herbal remedies and homeopathy. The most popular cancer patients have previously or currently undertaken conventional treatments and are now also trying complementary therapies to prolong life and delay or reduce the severity of their disease." - Anonymous Online Contributor
"Most cancer cases are thought to arise from either mutational errors during DNA replication or errors after DNA repair. Mutations are most common in tissues which have limited opportunity for cell division, such as skin or lung epithelium. Most errors are usually harmless, but cancers can sometimes arise or worsen when they become malignant. Mutational errors and mutations can happen spontaneously, but they may also develop under the influence of environmental toxicants. The most common cancers with significant environmental causation include lung, breast, and prostate. Epigenetic changes of tumour suppressor genes may also have a role. In many cases, a combination of genetics and environmental factors likely combine to produce many different types of cancer." - Anonymous Online Contributor
"The incidence of cancer is about 2.3 million a year within the United States and approximately 600,000 die of the disease annually. A full understanding of cancer incidence, prevention, and treatment should be the aim of clinical oncologists." - Anonymous Online Contributor
"Cancer is a disease in which abnormal cells grow out of control, invade normal tissue, and eventually destroy cells and tissues. Every cancer is unique, affecting a specific organ to a specific extent. Cancer is diagnosed based on symptoms and is confirmed by biopsy. The term "cancer" includes many types of cancer, and the label "cancer" is not a medical diagnosis. To provide the specific information and treatment needed, physicians rely on many factors and on the results of imaging techniques such as computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI)." - Anonymous Online Contributor
"The majority of lung tumor (non-small cell lung cancer) patients treated to date using rp-6306, a prolyl hydroxylase inhibitor, have had a durable response. Tumor progression that is not chemoresistant is sometimes observed and is best treated using agents, such as irinotecan, that are known to affect hypoxia (low oxygen levels) in tumors. A further chemotherapeutic and anti-angiogenic agent may have to be added to help overcome tumor progression. However, the use of drugs specifically targeting the proline prolyl hydroxylase pathway for lung cancer is not likely to yield lasting cures." - Anonymous Online Contributor
"Rp-6306 inhibited the growth of xenografted MCF-7 tumors in nude mice when given at 1.0 mg/kg/or less. Rp-6306 treatment decreased the number of MCF-7 cells in the bone marrow and decreased the level of serum IGF-I. Rp-6306 decreased the levels of STAT3 phosphorylation, increased the cell death fraction, and increased the level of p53 in MCF-7 cells. We hypothesize that Rp-6306 inhibited cellular processes by targeting the phosphorylation of STAT3 and its downstream transcription factors, and therefore inhibits the growth of MCF-7 cells." - Anonymous Online Contributor
"Although a clear trend toward increased survival was seen in these patients, this randomized study could not confirm the hypothesis that Rp-6306 is an effective treatment for mBC. Due to the low number of patients in this study, we are unable to draw conclusions concerning the safety or efficacy of this agent." - Anonymous Online Contributor
"The data show promising results in this preclinical model of [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) and may help guide future clinical investigations with rp-6306 for the treatment of patients with pancreatic cancer. Noble prize winner Dr. Otto H Warburg Cancer Research Center, New York University School of Medicine, M.D.\n" - Anonymous Online Contributor
"Only persons willing to be involved should be referred to cancer clinical trials. The trial should also be tailored to the preferences of the person and the available treatment opportunities." - Anonymous Online Contributor
"Findings from a recent study for the first group of the study were promising for clinical practice and may have important implications for health services. The second group was excluded. Rp-6306 is safe and well tolerated in patients with advanced cancer. Further research is required to establish the role of rp-6306 in the palliative care of a wider group of patients." - Anonymous Online Contributor